FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$2.5B
This Quarter Return
+30.23%
1 Year Return
+52.94%
3 Year Return
+530.54%
5 Year Return
–
10 Year Return
–
AUM
$1.87B
AUM Growth
+$1.87B
(+24%)
Cap. Flow
+$70.6M
Cap. Flow
% of AUM
3.78%
Top 10 Holdings %
Top 10 Hldgs %
59.4%
Holding
56
New
5
Increased
14
Reduced
4
Closed
7
Top Buys
| 1 |
89bio
ETNB
|
$22.3M |
| 2 |
Edgewise Therapeutics
EWTX
|
$19.9M |
| 3 |
Apellis Pharmaceuticals
APLS
|
$16.2M |
| 4 |
Madrigal Pharmaceuticals
MDGL
|
$16.1M |
| 5 |
Dyne Therapeutics
DYN
|
$15.8M |
Top Sells
| 1 |
Crinetics Pharmaceuticals
CRNX
|
$42.4M |
| 2 |
Enliven Therapeutics
ELVN
|
$14.3M |
| 3 |
Syndax Pharmaceuticals
SNDX
|
$8.71M |
| 4 |
Replimune Group
REPL
|
$6.62M |
| 5 |
Prothena Corp
PRTA
|
$6.17M |
Sector Composition
| 1 | Healthcare | 99.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
Enliven Therapeutics
ELVN
$1.24B
| – | – |
-1,050,483
| Closed | -$14.3M |
|
52
Passage Bio
PASG
$22.6M
| – | – |
-87,911
| Closed | -$1.16M |
|
|
53
Prothena Corp
PRTA
$452M
| – | – |
-127,900
| Closed | -$6.17M |
|
|
54
Replimune Group
REPL
$460M
| – | – |
-386,762
| Closed | -$6.62M |
|
|
55
Syndax Pharmaceuticals
SNDX
$1.39B
| – | – |
-600,000
| Closed | -$8.71M |
|
56
Sutro Biopharma
STRO
$85.6M
| – | – |
-780,000
| Closed | -$2.71M |
|